Literature DB >> 9593151

Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods.

M E Klepser1, E J Ernst, R E Lewis, M E Ernst, M A Pfaller.   

Abstract

This study was designed to examine the effects of antifungal carryover, agitation, and starting inoculum on the results of time-kill tests conducted with various Candida species. Two isolates each of Candida albicans, Candida tropicalis, and Candida glabrata were utilized. Test antifungal agents included fluconazole, amphotericin B, and LY303366. Time-kill tests were conducted in RPMI 1640 medium buffered with morpholinepropanesulfonic acid (MOPS) to a pH of 7.0 and incubated at 35 degrees C. Prior to testing, the existence of antifungal carryover was evaluated at antifungal concentrations ranging from 1x to 16x MIC by four plating methods: direct plating of 10, 30, and 100 microl of test suspension and filtration of 30 microl of test suspension through a 0.45-microm-pore-size filter. Time-kill curves were performed with each isolate at drug concentrations equal to 2 x MIC, using a starting inoculum of approximately 10(5) CFU/ml, and incubated with or without agitation. Last, inoculum experiments were conducted over three ranges of starting inocula: 5 x 10(2) to 1 x 10(4), >1 x 10(4) to 1 x 10(6), and >1 x 10(6) to 1 x 10(8) CFU/ml. Significant antifungal carryover (>25% reduction in CFU/milliliter from the control value) was observed with amphotericin B and fluconazole; however, carryover was eliminated with filtration. Agitation did not appreciably affect results. The starting inoculum did not significantly affect the activity of fluconazole or amphotericin B; however, the activity of LY303366 may be influenced by the starting inoculum. Before antifungal time-kill curve methods are routinely employed by investigators, methodology should be scrutinized and standardized procedures should be developed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593151      PMCID: PMC105779          DOI: 10.1128/AAC.42.5.1207

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Growth medium effect on the antifungal activity of LY 303366.

Authors:  M E Klepser; E J Ernst; M E Ernst; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1997-12       Impact factor: 2.803

Review 2.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

3.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

Authors:  M E Klepser; E J Wolfe; R N Jones; C H Nightingale; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.

Authors:  M E Klepser; E J Wolfe; M A Pfaller
Journal:  J Antimicrob Chemother       Date:  1998-03       Impact factor: 5.790

5.  In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.

Authors:  M A Pfaller; S A Messer; S Coffman
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

6.  Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.

Authors:  M E Ernst; M E Klepser; E J Wolfe; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1996 Nov-Dec       Impact factor: 2.803

7.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

  7 in total
  84 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 2.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

3.  Amphotericin primarily kills yeast by simply binding ergosterol.

Authors:  Kaitlyn C Gray; Daniel S Palacios; Ian Dailey; Matthew M Endo; Brice E Uno; Brandon C Wilcock; Martin D Burke
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

4.  In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans.

Authors:  Andreja Hasenoehrl; Tatjana Galic; Gabrijela Ergovic; Natasa Marsic; Mihael Skerlev; Joachim Mittendorf; Ulrich Geschke; Axel Schmidt; Wolfgang Schoenfeld
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

5.  In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.

Authors:  Jason Cota; Michael Carden; John R Graybill; Laura K Najvar; David S Burgess; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

6.  Slow response of invasive Candida krusei infection to amphotericin B in a clinical time-kill study.

Authors:  L Majoros; I Szegedi; G Kardos; C Erdész; J Kónya; C Kiss
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-12       Impact factor: 3.267

7.  Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.

Authors:  Vishnu Chaturvedi; Rama Ramani; David Andes; Daniel J Diekema; Michael A Pfaller; Mahmoud A Ghannoum; Cindy Knapp; Shawn R Lockhart; Luis Ostrosky-Zeichner; Thomas J Walsh; Karen Marchillo; Shawn Messer; Amanda R Welshenbaugh; Cara Bastulli; Noreen Iqbal; Victor L Paetznick; Jose Rodriguez; Tin Sein
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

8.  In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin.

Authors:  G Sóczó; G Kardos; I Varga; B Kelentey; R Gesztelyi; L Majoros
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

9.  In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect.

Authors:  S M Gunderson; H Hoffman; E J Ernst; M A Pfaller; M E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

10.  Magainin 2 induces bacterial cell death showing apoptotic properties.

Authors:  Wonyoung Lee; Dong Gun Lee
Journal:  Curr Microbiol       Date:  2014-07-15       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.